Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain-Training trial aims to turn down the ringing

NCT ID NCT07830069

NEW Symptom relief Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers at the University of Zurich are testing whether neurofeedback can ease chronic tinnitus, the persistent ringing or buzzing that affects hearing and quality of life. The study enrolls 24 adults with moderate to severe tinnitus for about nine months. Participants attend 20 neurofeedback sessions and 5 assessments, receiving both real and placebo feedback in a randomized crossover design. The goal is to measure changes in tinnitus loudness and distress, and to see how those changes relate to brain activity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
individualized EEG neurofeedback, a non-invasive brain-training technique
What this could lead to
If it works, neurofeedback could offer a drug-free way to turn down tinnitus loudness and the distress it causes. It could also give researchers a clearer map of the brain activity behind tinnitus.
What could go wrong
This is a small, early study of 24 people, and the specific neurofeedback method is new and untested. Placebo-controlled trials of brain training often show modest or short-lived effects, and results in this group may not apply to everyone with tinnitus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy female or male or diverse patients 18 years to 65 years of age * Persistent chronic, subjective tinnitus with duration of more than 3 months * Signed informed consent after being informed about the study * Fluent in German * Tinnitus with a THI Grade 2 to 4 (18-76 points), moderate to severe * Willing and able to attend all study visits Exclusion Criteria: * Hyperacusis * Concurrent neurological or psychiatric disorders * Regular intake of medication influencing the central nervous system (e.g. neuroleptics, hypnotics, sedatives, and anti-epileptics) * Somatic tinnitus * Asymmetrical hearing (more than 20dB side difference), pantonal hearing loss \> 40dB in any measured frequency up to 2kHz * Women who are pregnant and/or breast feeding * Intention to become pregnant during the course of the study * Known or suspected drug or alcohol abuse * Participation in another study with investigational drug within the 30 days preceding and during the present study, * Enrolment of the investigator, his/her family members, employees and other dependent persons

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tinnitus, subjective are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tinnitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tinnitus, subjective

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.